Schedule 7-OH First
The Case for Acting Before Vape Delivery Scales
The debate around kratom regulation has been tangled for nearly a decade — complicated by botanical complexity, traditional use history, and a pharmacological profile that resists easy classification.
7-hydroxymitragynine is not complicated.
The case for scheduling 7-OH is cleaner, faster, and more urgent than the broader kratom question — and the emergence of vape-format delivery makes delay indefensible.
What 7-OH Actually Is
7-hydroxymitragynine is not kratom. It shares a plant of origin — Mitragyna speciosa — but the compound sold in commercial 7-OH products is produced semisynthetically through the oxidation of mitragynine in a laboratory. The kratom branding on retail packaging is marketing, not botany.
At the receptor level, 7-OH is an opioid-class compound. It binds preferentially to mu-opioid receptors, produces physical dependence with a compressed timeline of use and escalation, and generates withdrawal that mirrors classical opioid withdrawal in both character and intensity. Animal studies have demonstrated cross-tolerance with opioids and naloxone-precipitated withdrawal consistent with opioid dependence.
This is not a gray area. The pharmacology is documented. The abuse liability is established. The FDA recommended scheduling in 2025.
The DEA has not yet acted.
What Is on the Retail Shelf Right Now
While regulatory processes move at their own pace, the retail landscape has not waited.
7-OH products are currently sold at gas stations, smoke shops, and vape retailers across the country. They appear as precisely dosed tablets, chewable gummies, shots, and now vaporized formats — products indistinguishable in appearance from legal supplements or nicotine alternatives.
Recent laboratory testing of commercially available 7-OH products found not just 7-OH but mixed alkaloid profiles including mitragynine pseudoindoxyl and paynantheine — compounds with additive mu-opioid receptor activity whose combined potency is neither standardized nor disclosed to consumers.
There is no federally mandated age verification. There is no standardized dosing information. There is no required disclosure that the product produces physical opioid-class dependence.
A parent has no reliable way to know their teenager is using one.
The Vape Problem Changes the Timeline
The introduction of vaporized 7-OH delivery is not an incremental product development. It is a category shift that materially increases the risk profile.
Oral 7-OH products — tablets, gummies, shots — have a delayed onset of ten to thirty minutes. That delay creates a natural spacing between dose and effect. Spacing creates intervals. Intervals allow some degree of nervous system recovery between doses.
Vaporized delivery eliminates that window.
Onset in seconds means the gap between discomfort and response effectively disappears. The behavioral pattern shifts from intermittent dosing toward continuous adjustment. The nervous system reorganizes around the absence of gaps rather than their presence.
This is the beginning of rapid-cycle reinforcement patterns that lock behavior into continuous use and drive a broader cascade of system instability rather than discrete episodes of use.
For an adult with an established baseline and some awareness of what is happening, this is a serious problem. For a teenager or young adult whose nervous system is still developing — who has no reference point for opioid-class dependence, no framework for what is happening to them, and a device in their pocket that looks identical to a nicotine vape — it is a different order of problem entirely.
Physical opioid-class dependence, delivered in a format with no friction, no visibility, and no age barrier.
That is what is on the market today.
Why 7-OH Is the Right Regulatory Target
The kratom question is genuinely complex. Kratom leaf contains over 50 alkaloids. It has a documented traditional use history spanning centuries in Southeast Asia. Its primary active compound, mitragynine, has a multi-receptor pharmacological profile that resists simple opioid classification. The consumer advocacy infrastructure around kratom is organized, vocal, and politically sophisticated.
None of that applies to 7-OH.
7-OH is a semisynthetic compound. It has no traditional use history. Its pharmacological profile at the mu-opioid receptor is well-characterized and unambiguous. It has no legitimate therapeutic application currently approved or pending. The retail products bearing its name carry no dosing standards, no safety disclosures, and no regulatory oversight.
The regulatory case is clean. The pharmacological case is clean. The public health urgency is immediate.
Starting with 7-OH does not resolve the broader kratom question — but it does not need to. It addresses the most acute, most accessible, and most rapidly escalating harm in the current landscape. It creates a scheduling precedent for semisynthetic kratom-derived compounds. And it removes the most dangerous products from open retail access while the longer kratom conversation continues.
Doing the harder thing first — attempting to resolve the full complexity of kratom before acting on the cleaner target — is not caution. It is a policy choice with a body count attached to it.
For Parents and the General Public
If you have a teenager or young adult in your life, this is not an abstract policy concern.
These products are at the gas station counter. They look like supplements. They look like vape pens. They do not look like opioid-class compounds that produce physical dependence — but that is what they are.
Ask questions. Look at what is in their room, their bag, their car. If you see a vape device or a small tablet product you don’t recognize, it is worth knowing what it is before assuming it is harmless.
The retail market moved faster than the regulation. Until that changes, awareness is the only available protection.
For Policymakers and Advocates
The FDA recommendation to schedule 7-OH is on the table. The pharmacological record supporting that recommendation is substantial and largely uncontested. The public health case — particularly given the emergence of vaporized delivery formats — is urgent.
The question is not whether 7-OH warrants scheduling. The evidence settled that question. The question is whether regulatory action will precede the next wave of product innovation or follow it.
It has followed it so far.
The window to act ahead of the curve is open. It will not stay open indefinitely.
Pivot Protocols is an independent behavioral health platform focused on stabilization-first support for people navigating kratom extract and 7-OH dependence. For the pharmacological background underlying this piece, see: 7-OH is not simply a stronger form of kratom.
Pivot Protocols is an independent behavioral health platform focused on stabilization-first support for people navigating kratom extract and 7-OH dependence. For the pharmacological background underlying this piece, see: why kratom and 7-OH function as fundamentally different substances.
About the Author
John Leonard is the founder of Pivot Protocols and has spent 23 years in frontline recovery program leadership, including as founder and board chairman of Redemption House. He writes on stabilization-first approaches to kratom extract and 7-OH dependence.
Optional (add at bottom)
Related: